Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer

Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer

Wesley Furnback,1 Elizabeth Wu,1 Cloe Ying Chee Koh,2 Jorge Fernando Nino de Rivera Guzman,2 Christian Kruhl,3 Rupesh Kotecha,4 Bruce CM Wang3 1Real Chemistry, New York, NY, USA; 2Novocure, Inc, Portsmouth, NH, USA; 3Novocure GmbH, Root, Switzerland; 4Department of Radiation Oncology, Miami Cancer I...

Full description

Saved in:
Bibliographic Details
Main Authors: Furnback W, Wu E, Koh CYC, Nino de Rivera Guzman JF, Kruhl C, Kotecha R, Wang BC
Format: Article
Language:English
Published: Dove Medical Press 2025-02-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
lung cancer
chemotherapy
immunotherapy
cost-effectiveness
tumor treating fields
Online Access:https://www.dovepress.com/estimating-the-cost-effectiveness-of-tumor-treating-fields-ttfields-th-peer-reviewed-fulltext-article-CEOR
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items